NEW YORK, July 13, 2017 /PRNewswire/ -- Mizuho
Americas today announced the appointment of Difei Yang as Executive Director, SMID Cap
Biotechnology Research, extending the reach of its US healthcare
equity analyst team. Based in New
York, Yang will report to Head of US Equity Research
Sheryl Skolnick.
Yang has been covering the sector for nearly a decade, most
recently serving as Managing Director at Aegis Capital. She has
also served in senior equity analyst roles at Brean Capital,
R.F. Lafferty, WallachBeth Capital
and Auriga Global Investors. In addition to her research expertise,
Yang has also held senior science and program management roles
within the pharmaceutical industry and has authored many granted US
patents and peer reviewed scientific publications. She holds a
Ph.D. in Chemistry from the University of
California Los Angeles as well as an MBA from Georgia State University.
"Continued investment in our US equity research platform to add
breadth and depth of investment insight for clients remains a
significant area of focus as we grow and expand in this market,"
said Matt DeSalvo, Head of Equities
at Mizuho Americas. "Yang will fortify our robust healthcare sector
coverage, bringing to the table abundant research expertise and an
esteemed scientific background."
Yang joins a growing Mizuho US healthcare equity research team
that includes large cap biotech analyst Salim Syed, as well as analysts covering the
healthcare services and pharmaceuticals sectors to deepen coverage
and explore small and mid-cap opportunities for biotechnology
investors. Mizuho has made a number of equity research appointments
in the past year, with the most recent additions being senior
internet and fintech analyst hires announced in May.
About Mizuho Americas
Mizuho Americas is a leading
financial institution comprising several legal entities, which
together offer clients corporate and investment banking, financing,
securities, treasury services, asset management, research and more.
With professionals in offices throughout the US, Canada, Mexico, Brazil and Chile, Mizuho's operations in the Americas
connect a broad client base of major corporations, financial
institutions and public sector groups to local markets and a vast
global network. Learn more at mizuhoamericas.com
Mizuho Americas is an integral part of the Japan-based Mizuho Financial Group, Inc.
(NYSE: MFG). Mizuho Financial Group is one of the largest financial
institutions in the world, offering comprehensive financial and
strategic services including private banking and venture capital
through its subsidiaries. The group has over 900 offices and 56,000
employees worldwide in nearly 40 countries throughout the Americas,
EMEA, and Asia. At the end of
2016, its total assets were $1.8
trillion. Learn more about Mizuho Financial Group at
https://www.mizuho-fg.com
View original
content:http://www.prnewswire.com/news-releases/mizuho-expands-healthcare-equity-research-with-smid-cap-biotechnology-hire-300487662.html
SOURCE Mizuho Americas